Granted Patent
B2
US 7,915,303 · App. 11/908,714 · Granted Mar 29, 2011
Glycopyrronium salts and their therapeutic use
Assignee:
Sosei R&D Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation.
Claims (3)
1. A glycopyrronium iodide, as a pair of diastereoisomers, having a glass transition temperature of 55° C.
2. The glycopyrronium iodide according to claim 1 , in milled form.
3. A dry powder inhaler comprising a glycopyrronium iodide according to claim 1 .
Assignments (4)
CHANGE OF NAME
Recorded Jul 16, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: NXERA PHARMA UK LIMITED
Reel/Frame 067998/0421 →
CHANGE OF ADDRESS FOR ASSIGNEE
Recorded Jul 16, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 068384/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 20, 2018
From: SOSEI R&D LTD.
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 047831/0220 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 13, 2008
From: BAXTER, ANDREW DOUGLAS
To: SOSEI R&D LTD.
Reel/Frame 021826/0446 →
Priority Claims (3)
GB 0506127.0
· Mar 24, 2005
· national
GB 0506129.6
· Mar 24, 2005
· national
GB 0523354.9
· Nov 16, 2005
· national
Continuity (1)